Drugs / Ipilimumab N01
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07683221 | Jul 2026 → Jul 2029 expected | malignant pancreatic neoplasm | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07422753 | Mar 2026 → Mar 2027 expected | hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07487662 | Mar 2026 → Mar 2028 expected | hepatocellular carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07506109 | Mar 2026 → Dec 2027 expected | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07643623 | Jun 2026 → Dec 2031 expected | adenocarcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval innoventbio.com ↗
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Innovent Biologics (Suzhou) Co. Ltd. | China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval innoventbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ipilimumab N01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07643623 ↗ |
| Action | Inhibit | “ipilimumab N01 (anti-CTLA-4)” NCT07506109 ↗ |
| Modality | Monoclonal antibody | “CTLA-4 Antibody(ipilimumab N01)” NCT07422753 ↗ |
| Route | Intravenous | “ipilimumab N01 (3mg/kg IV)” NCT07422753 ↗ |